BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IgA Nephropathy readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in IgA Nephropathy\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05003986-10808@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20270312
DTEND;VALUE=DATE:20270313
SUMMARY:Filspari (sparsentan): Phase 2 readout est. (NCT05003986)
DESCRIPTION:Filspari (sparsentan)\, phase 2\, Focal Segmental Glomeruloscle
 rosis.\nStudy: Study of Sparsentan Treatment in Pediatrics With Proteinuri
 c Glomerular Diseases\nEstimated primary completion: 12 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sparsentan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05003986
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935357-3402@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06935357)
DESCRIPTION:Felzartamab\, phase 3\, IgA Nephropathy.\nStudy: A Study to Lea
 rn About the Effects of Felzartamab Infusions on Adults With Immunoglobuli
 n A Nephropathy (IgAN)\nEstimated primary completion: 31 May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/felzartamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06935357
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052981-5453@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Telitacicept: Phase 3 readout est. (NCT07052981)
DESCRIPTION:Telitacicept\, phase 3\, IgA Nephropathy.\nStudy: Clinical Stud
 y on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric
  IgA Nephropathy or IgA Vasculitis Nephritis\nEstimated primary completion
 : 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telit
 acicept#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07052981
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05852938-909@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Zigakibart: Phase 3 readout est. (NCT05852938)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: A Study 
 of Zigakibart in Adults With IgA Nephropathy\nEstimated primary completion
 : 10 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zig
 akibart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05852938
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06774664-3146@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:SCTC21C: Phase 1/2 readout est. (NCT06774664)
DESCRIPTION:SCTC21C\, phase 1/2\, IgA Nephropathy.\nStudy: A Clinical Study
  of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/sctc21c#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06774664
URL:https://assetmemo.bio/drug/sctc21c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797518-887@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20271127
DTEND;VALUE=DATE:20271128
SUMMARY:Fabhalta (Iptacopan): Phase 2 readout est. (NCT06797518)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 2\, IgA Nephropathy.\nStudy: Study
  to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Ki
 dneys of Adult Patients With IgAN\nEstimated primary completion: 27 Novemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/iptacopan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067975
 18
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890909-10841@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20271212
DTEND;VALUE=DATE:20271213
SUMMARY:Povetacicept: Phase 3 readout est. (NCT07890909)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: A Phase 3b St
 udy of Participant Experience on Povetacicept Administered Via Autoinjecto
 r as Compared to Sibeprenlimab Administered Via Prefilled Syringe\nEstimat
 ed primary completion: 12 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07890909
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663204-10808@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Filspari (sparsentan): Phase 2 readout est. (NCT04663204)
DESCRIPTION:Filspari (sparsentan)\, phase 2\, IgA Nephropathy.\nStudy: A St
 udy of the Safety and Activity of Sparsentan for the Treatment of Patients
  With Immunoglobulin A Nephropathy\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sparsentan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0466
 3204
URL:https://assetmemo.bio/drug/sparsentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564142-10841@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Povetacicept: Phase 3 readout est. (NCT06564142)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: Evaluation of
  Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgA
 N)\nEstimated primary completion: 30 January 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06564142
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06419205-5759@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ebribafusp alfa: Phase 2 readout est. (NCT06419205)
DESCRIPTION:Ebribafusp alfa\, phase 2\, IgA Nephropathy.\nStudy: A Phase 2 
 Study to Evaluate the Safety\, PD\, PK\, and Clinical Activity of ADX-097 
 in Participants With IgAN\, LN or C3G\nEstimated primary completion: Febru
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ebribafusp-
 alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06419205
URL:https://assetmemo.bio/drug/ebribafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05732402-10841@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Povetacicept: Phase 1/2 readout est. (NCT05732402)
DESCRIPTION:Povetacicept\, phase 1/2\, IgA Nephropathy.\nStudy: An Open-lab
 el Study of Povetacicept in Autoantibody-Associated Glomerular Diseases\nE
 stimated primary completion: 2 March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/povetacicept#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05732402
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04573478-330@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT04573478)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: Atra
 sentan in Patients With IgA Nephropathy\nEstimated primary completion: 14 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atrasenta
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 573478
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04573478-909@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Zigakibart: Phase 3 readout est. (NCT04573478)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: Atrasent
 an in Patients With IgA Nephropathy\nEstimated primary completion: 14 Apri
 l 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zigakibart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045734
 78
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797610-5037@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280525
DTEND;VALUE=DATE:20280526
SUMMARY:Sefaxersen: Phase 3 readout est. (NCT05797610)
DESCRIPTION:Sefaxersen\, phase 3\, IgA Nephropathy.\nStudy: A Study to Eval
 uate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants Wit
 h Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression\n
 Estimated primary completion: 25 May 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sefaxersen#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05797610
URL:https://assetmemo.bio/drug/sefaxersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07522099-5453@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280710
DTEND;VALUE=DATE:20280711
SUMMARY:Telitacicept: Phase 2 readout est. (NCT07522099)
DESCRIPTION:Telitacicept\, phase 2\, IgA Nephropathy.\nStudy: Chinese Adult
 s With Kidney Disease\nEstimated primary completion: 10 July 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/telitacicept#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07522099
URL:https://assetmemo.bio/drug/telitacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889362-3402@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Felzartamab: Phase 2 readout est. (NCT07889362)
DESCRIPTION:Felzartamab\, phase 2\, IgA Nephropathy.\nStudy: A Study to Lea
 rn About the Effects of Felzartamab on the Kidneys of Adults With Immunogl
 obulin A Nephropathy (IgAN)\nEstimated primary completion: 13 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/felzartamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07889362
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963827-3188@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280907
DTEND;VALUE=DATE:20280908
SUMMARY:Mezagitamab: Phase 3 readout est. (NCT06963827)
DESCRIPTION:Mezagitamab\, phase 3\, Chronic Kidney Disease.\nStudy: A Study
  of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy\nEs
 timated primary completion: 7 September 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/mezagitamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06963827
URL:https://assetmemo.bio/drug/mezagitamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850752-330@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280917
DTEND;VALUE=DATE:20280918
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT07850752)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: A St
 udy of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patient
 s With Primary IgA Nephropathy\nEstimated primary completion: 17 September
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/atrasentan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0785075
 2
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024563-885@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20281129
DTEND;VALUE=DATE:20281130
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT07024563)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, IgA Nephropathy.\nStudy: St
 udy of Ravulizumab in Pediatric Participants With Primary IgAN\nEstimated 
 primary completion: 29 November 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ravulizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07024563
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541287-10888@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:JADE101: Phase 2 readout est. (NCT07541287)
DESCRIPTION:JADE101\, phase 2\, IgA Nephropathy.\nStudy: A Study of JADE101
  in Participants With Immunoglobulin A Nephropathy\nEstimated primary comp
 letion: January 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /jade101#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07541287
URL:https://assetmemo.bio/drug/jade101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902817-10888@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:JADE101: Phase 3 readout est. (NCT07902817)
DESCRIPTION:JADE101\, phase 3\, IgA Nephropathy.\nStudy: A Phase 3 Blinded 
 Study of JADE101 in Participants With Immunoglobulin A Nephropathy\nEstima
 ted primary completion: June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/jade101#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07902817
URL:https://assetmemo.bio/drug/jade101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807995-10841@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20291228
DTEND;VALUE=DATE:20291229
SUMMARY:Povetacicept: Phase 3 readout est. (NCT07807995)
DESCRIPTION:Povetacicept\, phase 3\, IgA Nephropathy.\nStudy: A Phase 3 Ope
 n-Label Study of Long-term Treatment With Povetacicept in Adults With Immu
 noglobulin A Nephropathy\nEstimated primary completion: 28 December 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/povetacicept#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07807995
URL:https://assetmemo.bio/drug/povetacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06994845-887@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20300628
DTEND;VALUE=DATE:20300629
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06994845)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, IgA Nephropathy.\nStudy: Study
  to Assess the Efficacy\, Pharmacokinetics\, Safety and Tolerability of Ip
 tacopan in Pediatric Patients With Primary IgAN\nEstimated primary complet
 ion: 28 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 tacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06994845
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146906-909@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20300712
DTEND;VALUE=DATE:20300713
SUMMARY:Zigakibart: Phase 2 readout est. (NCT07146906)
DESCRIPTION:Zigakibart\, phase 2\, Chronic Kidney Disease.\nStudy: A Study 
 to Assess the Effects of Zigakibart on IgA Nephropathy.\nEstimated primary
  completion: 12 July 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/zigakibart#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07146906
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557462-887@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20301204
DTEND;VALUE=DATE:20301205
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04557462)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Chronic Kidney Disease.\nStudy
 : A Rollover Extension Program (REP) to Evaluate the Long-term Safety and 
 Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary I
 gA Nephropathy\nEstimated primary completion: 4 December 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/iptacopan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04557462
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06674577-5425@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20310521
DTEND;VALUE=DATE:20310522
SUMMARY:Atacicept: Phase 2 readout est. (NCT06674577)
DESCRIPTION:Atacicept\, phase 2\, IgA Nephropathy.\nStudy: A Rollover Study
  to Evaluate the Long-Term Safety and Efficacy of Atacicept\nEstimated pri
 mary completion: 21 May 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/atacicept#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06674577
URL:https://assetmemo.bio/drug/atacicept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858319-909@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20310625
DTEND;VALUE=DATE:20310626
SUMMARY:Zigakibart: Phase 3 readout est. (NCT06858319)
DESCRIPTION:Zigakibart\, phase 3\, Chronic Kidney Disease.\nStudy: Open-lab
 el Extension Study of Zigakibart in Adults With IgA Nephropathy.\nEstimate
 d primary completion: 25 June 2031. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/zigakibart#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06858319
URL:https://assetmemo.bio/drug/zigakibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07498335-330@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20310915
DTEND;VALUE=DATE:20310916
SUMMARY:Vanrafia (Atrasentan): Phase 3 readout est. (NCT07498335)
DESCRIPTION:Vanrafia (Atrasentan)\, phase 3\, IgA Nephropathy.\nStudy: Stud
 y to Assess the Efficacy\, Pharmacokinetics\, Safety and Tolerability of A
 trasentan in Pediatric Patients With Primary IgAN\nEstimated primary compl
 etion: 15 September 2031. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atrasentan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07498335
URL:https://assetmemo.bio/drug/atrasentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
